# Rapport Therapeutics, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Rapport Therapeutics, Inc.). ## Overview Rapport Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company focused on discovering and developing small-molecule medicines for neurological and psychiatric disorders. Its lead program, RAP-219, is being advanced for focal onset seizures, supported by the company’s RAP technology platform and licensed neuroscience assets. ## Products & services • RAP-219 small-molecule product candidate • RAP technology platform for precision neuroscience • Discovery and preclinical development of neurological assets • Clinical development for focal onset seizures • Licensed TARPγ8 and nAChR-related programs - **Clinical-stage product candidates** (0%) — Small-molecule drug candidates being advanced through preclinical and clinical development. - **Precision neuroscience platform** (0%) — Internal discovery platform used to identify and develop RAP-targeted therapies. - **Licensed neuroscience assets** (0%) — In-licensed TARPγ8 and nAChR programs and related know-how from Janssen. - **Research and development services** (100%) — External CRO, CMO, and clinical trial services used to advance product candidates. - RAP-219 small-molecule product candidate - RAP technology platform for precision neuroscience - Discovery and preclinical development of neurological assets - Clinical development for focal onset seizures - Licensed TARPγ8 and nAChR-related programs ## Customers Rapport does not yet sell commercial products; its near-term counterparties are clinical investigators, contract research organizations, contract manufacturers, and specialized clinical partners that support development. If approved, its therapies would be used by patients with focal onset seizures and potentially other neurological or psychiatric disorders, with reimbursement decisions made by payors and adoption driven by neurologists and other prescribers. - **Clinical development partners** (primary) — CROs, CMOs, and trial vendors that provide preclinical, clinical, and manufacturing services. - **Clinical trial investigators and sites** (primary) — Hospitals and research sites that enroll patients and execute RAP-219 studies. - **Neurology patients** (primary) — Patients with focal onset seizures who would be treated if RAP-219 is approved. - **Prescribers and specialists** (secondary) — Neurologists and other specialists who would evaluate efficacy, safety, and convenience. - **Third-party payors** (secondary) — Commercial and government payors that determine coverage and reimbursement. - Clinical trial sites and investigators running RAP-219 studies - CROs and CMOs providing research, testing, and manufacturing - Neurologists treating focal onset seizures if products are approved - Patients with neurological or psychiatric disorders as end users - Third-party payors that influence access and reimbursement ## Geography Rapport is headquartered in the United States and conducts its business primarily through U.S.-based corporate, research, and clinical development activities. Its operational footprint is shaped by where it can source scientific talent, run clinical trials, and contract with specialized vendors; no country-level revenue disclosure is available because the company is pre-commercial. - Headquartered in the United States - Clinical and research operations are centered in the U.S. - Trial execution depends on U.S. and potentially global sites - Manufacturing is outsourced through CMOs rather than owned plants - No country revenue mix disclosed because the company is pre-commercial ## Strategy The company’s strategy is to use its RAP platform to build a pipeline of precision neuroscience medicines, with RAP-219 as the lead asset. It also relies on external partners and licensed intellectual property to accelerate development while preserving flexibility to add new product candidates over time. - **Advance RAP-219 clinical development** (short-term) — Clinical data are the main value driver for a pre-commercial biotech. - **Expand the pipeline beyond RAP-219** (medium-term) — A broader pipeline reduces single-asset dependence and supports long-term growth. - **Secure development and manufacturing capabilities** (medium-term) — Clinical and future commercial supply depend on reliable CRO/CMO execution. - Advance RAP-219 through clinical proof-of-concept - Use the RAP platform to discover additional neuroscience assets - Leverage the Janssen license for patents, materials, and know-how - Outsource development and manufacturing to specialized partners - Build a future commercial path in focal onset seizures and related disorders ## Risks Rapport faces the typical risks of a clinical-stage biotech: uncertain clinical outcomes, regulatory risk, and the need for substantial future capital. Because it has no approved products, its business also depends on successful IP protection, outsourced manufacturing, and eventual reimbursement and market acceptance if any candidate is commercialized. - **Clinical development failure** [critical] — RAP-219 and future candidates may not demonstrate sufficient efficacy or safety. - **Capital dependence** [high] — The company has no product revenue and will need future financing to fund R&D. - **Manufacturing and supply chain execution** [high] — Commercial-scale drug substance and drug product processes are still being developed. - **Competitive pressure** [medium] — Epilepsy and neuroscience markets include large pharma, generics, devices, and surgeries. - **Reimbursement and market access** [medium] — Any approved product must win coverage and reimbursement to achieve adoption. - Clinical trials may fail to show efficacy or acceptable safety - Regulatory approval is uncertain and can be delayed or denied - The company will need substantial additional capital over time - Outsourced manufacturing may not scale reliably or cost-effectively - Competition from established epilepsy therapies and larger biopharma is intense ## Accounting As a pre-revenue biotech, the most important accounting judgments are research and development expense recognition, accruals for CRO/CMO and clinical trial services, and valuation of prepaid or milestone-based arrangements. The company also relies on estimates for stock-based compensation, fair value measurements of cash equivalents and short-term investments, and potential impairment or write-off risk if licensed assets or capitalized costs lose value. - **Research and development accruals** — Can shift quarterly R&D expense and prepaid balances - **Milestone-based vendor contracts** — Affects timing of expense recognition and liabilities - **Short-term investment valuation** — Influences liquidity presentation and interest income - **Stock-based compensation** — Affects operating loss and diluted share count - R&D expense accruals for clinical trial and manufacturing vendors - Milestone-based service contracts such as the NeuroPace SOWs - Prepaid expenses and timing of vendor deliverables - Fair value accounting for cash equivalents and short-term investments - Stock-based compensation and other estimate-driven public company costs --- *Last updated: 2026-04-29T04:53:01.854000+00:00*